Global Forecast for Urinary Tract Infection Treatment Market, Including Anticipated Size
The global market for urinary tract infection (UTI) treatments is expected to reach a significant value of around US$ 10.73 billion by 2030, as revealed in a new report published by Renub Research. The comprehensive study titled "Urinary Tract Infection Treatment Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2030" delves into various aspects of the market, including competition, geographic distribution, and growth potential.
Effective treatment for UTIs is crucial in preventing complications and alleviating discomfort. The report highlights that treatment not only addresses symptoms but also helps reduce the risk of antibiotic resistance among uro-pathogens. Untreated UTIs can lead to severe kidney infections and long-term complications.
The growth of the UTI treatment market is primarily driven by the introduction of new therapies with improved clinical profiles. These include Tebipenem Pivoxil Hydrobromide (SPR994), ZAYNICH (zidebactam/cefepime), Cefepime/Taniborbactam, and Nacubactam. These advanced therapies enhance treatment options for complicated UTIs, leading to increased market penetration and adoption.
Rising awareness about UTIs, particularly complicated types, along with increased government funding for research and healthcare infrastructure, significantly supports market expansion. This encourages the development and availability of novel therapeutics.
The aging global population, which is more prone to infections and requires long-term care, drives demand for UTI treatments and related products such as urinary bags. The increase in chronic diseases and elderly patients contributes to a sustained market demand.
Improvements in healthcare infrastructure, increased healthcare spending, and integration of technological innovations (including AI in diagnostics and personalized medicine) facilitate early diagnosis and effective management of UTIs. Point-of-care testing and telemedicine also support better disease management, boosting treatment market growth.
The report provides a detailed breakup of the market from 17 viewpoints, including major countries like the United States, Canada, Mexico, Brazil, United Kingdom, Germany, France, Italy, Spain, Netherlands, China, Japan, India, South Korea, Australia, South Africa, and United Arab Emirates.
Leading companies in the global market for UTI treatments include AstraZeneca, Bayer AG, GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG, Pfizer, Merck & Co. Inc., Dr. Reddy's Laboratories Ltd., and Bristol-Myers Squibb Company.
Renub Research, a renowned Market Research and Information Analysis company with over 15 years of experience, has published more than 9000 syndicated reports and worked on over 750 custom research projects. Contact information for Renub Research can be found on their website or through their Marketing Manager, Rajat Gupta.
In addition to the UTI treatment market report, Renub Research has also published a report titled "Liposuction Surgery Device Market, Size, Global Forecast, Growth, Companies Analysis." The report provides insights into the competition, geographic distribution, and growth potential for the Liposuction Surgery Device Market.
The global market for gynecology applications is experiencing a remarkable increase in the international urinary tract infection treatment market. Cephalosporin antibiotics are witnessing substantial growth in the usage of cephalosporins in the UTI treatment market due to their broad-spectrum efficacy towards uro-pathogens.
For more detailed information, readers are encouraged to access the full report on the Renub Research website.
[1] Renub Research. (2021). Urinary Tract Infection Treatment Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2030. [2] Grand View Research. (2020). Urinary Tract Infection Treatment Market Size, Share & Trends Analysis Report By Drug Class (Penicillin & Combinations, Quinolones, Cephalosporin, Aminoglycoside Antibiotics, Sulphonamides (Sulfamethoxazole + Trimethoprim), Azoles and Amphotericin B, Tetracycline (Doxycycline), Nitrofurans (Nitrofurantoin), and Others), By Distribution Channel (Hospitals, Gynecology & Urology Clinics, Drug Stores, Retail Pharmacies, and Online Drug Stores), By Region, and Segment Forecasts, 2020 - 2028. [3] MarketsandMarkets. (2020). Urinalysis Market by Test Type (Dipstick, Microscopy, Culture, Immunoassay, Nucleic Acid Amplification Test (NAAT), and Others), by End User (Hospitals & Diagnostic Centers, Research Institutes, and Others), and by Region - Global Forecast to 2025. [4] Grand View Research. (2020). Urinary Incontinence Devices Market Size, Share & Trends Analysis Report By Product (Adult Diapers, Male Incontinence Products, Female Incontinence Products, Catheters, and Others), By Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies, and Others), By Region, and Segment Forecasts, 2020 - 2028.
Scientists are studying advanced therapies, such as Tebipenem Pivoxil Hydrobromide (SPR994), ZAYNICH (zidebactam/cefepime), Cefepime/Taniborbactam, and Nacubactam, to improve the treatment of medical-conditions like urinary tract infections (UTIs). These new therapies not only help alleviate symptoms of UTIs but also contribute to health-and-wellness by reducing the risk of antibiotic resistance among uro-pathogens and prevent complications like kidney infections.
